Cagrilintide vs Tirzepatide
Comparing Novo Nordisk's amylin analog cagrilintide with Eli Lilly's dual GIP/GLP-1 agonist tirzepatide.
Last updated: February 1, 2026
Cagrilintide
Tirzepatide
Overview
Cagrilintide and tirzepatide target obesity through entirely different mechanisms. Cagrilintide is a long-acting amylin analog developed as a combination partner (CagriSema), while tirzepatide is a dual GIP/GLP-1 agonist that achieved record weight loss in trials. This comparison highlights different pharmaceutical strategies in obesity treatment.
Mechanism Comparison
| Aspect | Cagrilintide | Tirzepatide |
|---|---|---|
| Target Receptors | Amylin (AMY1-3) | GIP + GLP-1 |
| Hormone Class | Amylin analog | Incretin dual agonist |
| Primary Brain Site | Area postrema | Hypothalamus |
| Insulin Effect | Indirect | Direct enhancement |
Different Satiety Pathways
Cagrilintide:
- Amylin signals meal-ending satiety
- Acts on area postrema and nucleus tractus solitarius
- Slows gastric emptying
- Complements GLP-1 effects
Tirzepatide:
- GLP-1 provides appetite suppression
- GIP adds metabolic benefits
- Acts primarily on hypothalamus
- Enhances insulin sensitivity
Evidence Comparison
| Aspect | Cagrilintide | Tirzepatide |
|---|---|---|
| Monotherapy Trials | Phase 2 | Phase 3 + Approved |
| Regulatory Status | Investigational | FDA Approved |
| Primary Strategy | Combination (CagriSema) | Standalone |
| Evidence Base | Moderate | Extensive |
Efficacy Comparison
Cagrilintide Monotherapy (Phase 2)
| Dose | Weight Loss (26 weeks) |
|---|---|
| 2.4mg | ~9% |
| 4.5mg | ~11% |
CagriSema (Cagrilintide + Semaglutide)
| Comparison | Weight Loss |
|---|---|
| CagriSema | ~15-22% |
| Semaglutide alone | ~15% |
Tirzepatide (SURMOUNT-1)
| Dose | Weight Loss (72 weeks) |
|---|---|
| 10mg | ~19.5% |
| 15mg | ~22.5% |
Comparison: Tirzepatide monotherapy achieves similar or better results than cagrilintide + semaglutide combination.
Strategic Positioning
| Factor | Cagrilintide | Tirzepatide |
|---|---|---|
| Company | Novo Nordisk | Eli Lilly |
| Standalone Viability | Low | Yes |
| Combination Partner | Primary value | Not needed |
| Competitive Response | To tirzepatide | First-in-class |
The Cagrilintide Strategy
Novo Nordisk’s response to tirzepatide:
- Semaglutide alone ~15% weight loss
- Tirzepatide ~22% weight loss (competitive threat)
- CagriSema (semaglutide + cagrilintide) targets ~20%+ weight loss
- Maintains Novo’s competitive position
Regulatory Status
| Aspect | Cagrilintide | Tirzepatide |
|---|---|---|
| FDA Status | Investigational | Approved |
| Brand Names | N/A | Mounjaro, Zepbound |
| CagriSema Status | Phase 3 | N/A |
| Timeline | CagriSema 2025-2026 | Available now |
Side Effect Profile
| Effect | Cagrilintide | Tirzepatide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| Constipation | More prominent | Less prominent |
| Overall GI | Class effects | Class effects |
Administration
| Aspect | Cagrilintide | Tirzepatide |
|---|---|---|
| Route | Subcutaneous | Subcutaneous |
| Combination | With semaglutide (CagriSema) | Standalone |
| Injection Burden | 1 (fixed combo) | 1 |
Cost and Access Considerations
| Factor | CagriSema (Future) | Tirzepatide |
|---|---|---|
| Pricing | Premium expected | ~$1,000+/month |
| Complexity | Two peptides | One peptide |
| Supply | TBD | Current shortages |
Key Differences
- Mechanism: Amylin vs dual incretin agonism
- Standalone efficacy: Cagrilintide moderate alone, tirzepatide highly effective alone
- Strategy: Cagrilintide is a combination partner; tirzepatide is standalone
- Approval status: Tirzepatide approved; cagrilintide investigational
- Company: Novo Nordisk vs Eli Lilly
Summary
- Cagrilintide is an amylin analog primarily valuable as part of CagriSema combination
- Tirzepatide is the first dual GIP/GLP-1 agonist with class-leading efficacy
- CagriSema (cagrilintide + semaglutide) aims to match tirzepatide’s efficacy
- Different mechanisms represent distinct approaches to obesity
- Tirzepatide’s approval and efficacy make it the current benchmark
This comparison is for educational purposes only. Cagrilintide is investigational. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.